Mon, August 31, 2009
Fri, August 28, 2009
Thu, August 27, 2009
Wed, August 26, 2009
Tue, August 25, 2009
Mon, August 24, 2009
Sun, August 23, 2009
Fri, August 21, 2009
Thu, August 20, 2009
Wed, August 19, 2009
Tue, August 18, 2009
Mon, August 17, 2009
Sun, August 16, 2009
Fri, August 14, 2009
Thu, August 13, 2009
Wed, August 12, 2009
Tue, August 11, 2009
Mon, August 10, 2009
Fri, August 7, 2009
Thu, August 6, 2009
Wed, August 5, 2009
Tue, August 4, 2009
Mon, August 3, 2009
Sat, August 1, 2009
Fri, July 31, 2009
Thu, July 30, 2009
Wed, July 29, 2009
Tue, July 28, 2009
Mon, July 27, 2009
Sat, July 25, 2009
Fri, July 24, 2009
Thu, July 23, 2009
Wed, July 22, 2009
Tue, July 21, 2009
Mon, July 20, 2009
Sun, July 19, 2009
Fri, July 17, 2009
Thu, July 16, 2009
Wed, July 15, 2009
Tue, July 14, 2009
Mon, July 13, 2009
Fri, July 10, 2009
Thu, July 9, 2009
Wed, July 8, 2009
Tue, July 7, 2009
Mon, July 6, 2009
Fri, July 3, 2009
Thu, July 2, 2009
Wed, July 1, 2009
Tue, June 30, 2009
Mon, June 29, 2009

SciClone Pharmaceuticals, Inc.: SciClone Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare C


//health-fitness.news-articles.net/content/2009/ .. al-markets-9th-annual-focus-on-healthcare-c.html
Published in Health and Fitness on Friday, July 31st 2009 at 14:37 GMT, Last Modified on 2009-07-31 14:38:03 by Market Wire   Print publication without navigation


FOSTER CITY, CA--(Marketwire - July 31, 2009) - SciClone Pharmaceuticals, Inc. (NASDAQ: [ SCLN ]) today announced that it will present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City. Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer, will present a corporate overview and business update on Wednesday, August 5, 2009 at 1:45 pm ET.

To access the live audio webcast of the presentation, please log on through a link located in the Investor Relations section of SciClone's website at [ www.sciclone.com ].

About SciClone

SciClone Pharmaceuticals (NASDAQ: [ SCLN ]) is a profit-driven, global biopharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and expense management. ZADAXIN (thymalfasin/thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin for stage IV melanoma, for which SciClone has reached agreement with the FDA on the design of a phase 3 trial; RP101 in a phase 2 trial for the treatment of pancreatic cancer; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; SCV-07 with a ready-to-initiate phase 2 trial for the treatment of HCV. SciClone has exclusive marketing rights to DC Bead™ in China, where the product is under regulatory review. The Company also has commercialization rights to an anti-nausea drug ondansetron RapidFilm™ in China and Vietnam, for which it is seeking regulatory approval. For additional information, please visit [ www.sciclone.com ].


Publication Contributing Sources

Similar Health and Fitness Publications